Subject Index

to Volume 35

A

abciximab
  disappoints as therapy for ACS, shows promise as adjunct to stenting for acute MI, 797 (Oct)
  infusion preparation procedure saves $30,000 annually, 448 (May)
  infusion preparation procedure saves even more, 451 (May)
ACE inhibitors
  CHF pathway increases prescribing of, 185 (Feb)
  use in type 2 diabetes slows ESRD progression at relatively low cost (abstr), 87 (Jan)
acid-related disorders
  esomeprazole (Nexium), Focus on, 882 (Nov)
acute coronary syndrome
  GP IIb/IIIa inhibitor therapy is cost-effective, but not cost saving in, 363 (April)
  no need to wait to start lipid-lowering drugs, following event, 447 (May)
adverse drug events
  one institution's management approach shared, 690 (Aug)
alendronate sodium tablets
  Fosamax, update on, 872 (Nov), 946 (Dec)
alosetron HCl tablets
  Lotronex, Focus on, 404 (May)
  Lotronex, update on, 297 (April)
alpha blockers
  not recommended in hypertension, interim ALLHAT findings show, 395 (May)
aminolevulinic acid HCl for topical solution 20%
  Levulan Kerastick, update on 113 (Feb)
amlodipine
  switch to felodipine ER, 435 (May)
amphotericin B liposome for injection
  AmBisome, update on, 306 (April), 792 (Oct)
amprenavir oral solution
  Agenerase, update on, 560 (July)
anastrozole tablets
  Arimidex, update on, 871 (Nov)
anemia in end-stage renal disease
  comparative considerations of parenteral iron products for, 498 (June)
angina
  fatty acid oxidation agent with minimum hemodynamic effects, effective for, 446 (May)
antihemophilic factor, recombinant
  Helixate FS, update on, 632 (Aug)
  Kogenate FS, update on, 632 (Aug)
  ReFacto, update on, 393 (May)
antileukotriene agents
  role of agents in management of asthma, 38 (Jan)
antimicrobial cost and coverage
  software aids in determination of, 842 (Oct)
antimicrobial prophylaxis
  using CQI process to change surgical practices, 53 (Jan)
antimicrobial shortages
  forcing widespread use of nonpreferred therapies, survey finds, 307 (April)
apomorphine
  Uprima, Focus on, 573 (July)
appropriate use protocols
  palatable alternative to prior authorization, 77 (Jan)
argatroban injection
  Argatroban, update on, 709, (Sept)
arsenic trioxide injection
  Trisenox, update on, 868 (Nov)
aspirin/extended-release dipyridamole
  Aggrenox, update on, 16 (Jan)
asthma
  monocloncal antibiody improves symptoms, reduces steroid use in hard-to-treat disease, 214 (Mar)
  role of antileukotriene agents in management of, 38 (Jan)
atorvastatin calcium tablets
  Lipitor, update on, 209 (Mar)
atovaquone and proguanil HCl tablets
  Malarone, update on, 713 (Sept)
atrial fibrillation
  AHQR evidence report assesses therapies for new-onset disease, 721 (Sept)
attention-deficit/hyperactivity disorder
  intensive medication management superior to routine care in treatment of, 214 (Mar)
azelastine HCl ophthalmic solution 0.05%
  Optivar, update on, 560 (July)
azithromycin
  favored over recommended regimen for hospitalized patients with community-acquired pneumonia, 311 (April)

B

balsalazide disodium capsules
  Colazal, update on, 709 (Sept)
BCG intravesical immunotherapy with live, attenuated mycobacteria
  Pacis, update on, 394 (May)
beclomethasone dipropionate HFA inhalation aerosol
  Qvar, update on, 872 (Nov)
benefit design
  pitfalls to three-tier benefit design, advantages, glimpes of future design, 75 (Jan)
  three-tier offers superficial solution to utilization challenges, PacifiCare director says, 599 (July)
bexarotene capsules
  Targretin, update on, 206 (Mar)
bexarotene gel 1%
  Targretin Gel, 634 (Aug)
biotechnology drugs
  a critical assessment of agents (part 2), 256 (Mar)
bipolar disorder
  consensus report updates guidelines for Tx of, 479 (June)
breast cancer
  study supports first-line combination endocrine therapy for premenopausal women, 128 (Feb)
  tamoxifen for prevention called one of the most cost-effective interventions, 307 (April)
budesonide inhlation suspension, 0.25 mg and 0.5 mg
  Pulmicort Respules, update on, 796 (Oct)

C

caffeine citrate oral solution
  Cafcit Oral Solution, update on, 478 (June)
cancer
  ASCO meeting spotlights advances in, 644 (Aug)
candesartan cilexetil/hydrochlorothiazide tablets
  Atacand HCT, update on, 871 (Nov)
cefdinir capsules
  Omnicef, update on, 21 (Jan)
celecoxib
  prior authorization policy expected to save Medicaid HMO over $700,000 annually, 775 (Sept)
cerivastatin sodium tablets
  Baycol, update on, 713 (Sept)
cetrorelix acetate for injection
  Cetrotide, update on, 791 (Oct)
cevimeline HCl capsules
  Evoxac, update on, 205 (Mar)
chemotherapy
  protocol improves safe use of agents, 185 (Feb)
  rounding-down dose preserves vials, yields substantial cost savings, 369 (April)
choriogonadotropin alfa for injection
  Ovidrel, update on, 872 (Nov)
ciclopirox 0.77% gel
  Loprox Gel, update on, 390 (May)
ciclopirox topical solution 8%
  Penlac Nail Lacquer, update on, 390 (May)
ciprofloxacin
  associated with smaller antibiotic cost increases; resistance tied to ofloxacin (abstr), 87 (Jan)
  more efficacious, less costly then TMP/SMX for acute uncomplicated pyelonephritis (abstr), 454 (May)
cisapride tablets, suspension
  Propulsid, update on, 306 (April)
citalopram HBr oral solution
  Celexa, update on, 118 (Feb)
clarithromycin extended-release tablets
  Biaxin XL Filmtab, update on, 390 (May), 946 (Dec)
clonidine HCl injection
  Duraclon, update on, 306 (April)
  halves risk of myocardial ischemia throughout perioperative period, 874 (Nov)
colesevelam HCl tablets
  Welchol, update on, 557 (July)
congestive heart failure
  NSAIDs raise risk of hospitalization for, 479 (June)
constipation
  new approach targets 5-HT4 receptor, increases bowel frequency, 641 (Aug)
COX-2 agents
  automated pharmacy edits ensure proper use without excessive prior authorizations, 599 (July)
  celecoxib 'PA' policy expected to save Medicaid HMO over $700,000 annually, 775 (Sept)
  have differential renal effects in older hypertensive patients, 957 (Dec)
  impact on NSAID and GI drug use and cost in practice, 71 (Jan)
  long-term trial finds fewer serious GI effects compared with traditional NSAIDs, 480 (June)
  meloxicam (Mobic), Focus on, 317 (April)
  rofecoxib induces significantly fewer GI events than nonselective NSAIDs (abstr), 190 (Feb)
crotalide polyvalent immune Fab (ovine)
  CroFab, update on, 946 (Dec)

D

database analysis
  use of multiple logistic regression in, 832 (Oct)
decision analysis
  use in modeling the cost-effectiveness of oral vs SC sumatriptan, 532 (June)
deep vein thrombosis
  tinzaparin (Innohep), Focus on, 725 (Sept)
  tinzaparin (Innohep), update on, 710 (Sept)
depression
  nortriptyline superior to fluoxetine in first comparative trial for post-stroke side effect (abstr), 453 (May)
dexmedetomidine HCl injection
  Precedex, update on, 113 (Feb)
diabetes
  ACE inhbitor use slows ESRD progression at relatively low cost (abstr), 87 (Jan)
  antihypertension Tx with beta blockers, but not diuretics, raise risk of (abstr), 453 (May)
  nateglinide (Starlix), Focus on, 798

Subject Index

to Volume 35

A

abciximab
  disappoints as therapy for ACS, shows promise as adjunct to stenting for acute MI, 797 (Oct)
  infusion preparation procedure saves $30,000 annually, 448 (May)
  infusion preparation procedure saves even more, 451 (May)
ACE inhibitors
  CHF pathway increases prescribing of, 185 (Feb)
  use in type 2 diabetes slows ESRD progression at relatively low cost (abstr), 87 (Jan)
acid-related disorders
  esomeprazole (Nexium), Focus on, 882 (Nov)
acute coronary syndrome
  GP IIb/IIIa inhibitor therapy is cost-effective, but not cost saving in, 363 (April)
  no need to wait to start lipid-lowering drugs, following event, 447 (May)
adverse drug events
  one institution's management approach shared, 690 (Aug)
alendronate sodium tablets
  Fosamax, update on, 872 (Nov), 946 (Dec)
alosetron HCl tablets
  Lotronex, Focus on, 404 (May)
  Lotronex, update on, 297 (April)
alpha blockers
  not recommended in hypertension, interim ALLHAT findings show, 395 (May)
aminolevulinic acid HCl for topical solution 20%
  Levulan Kerastick, update on 113 (Feb)
amlodipine
  switch to felodipine ER, 435 (May)
amphotericin B liposome for injection
  AmBisome, update on, 306 (April), 792 (Oct)
amprenavir oral solution
  Agenerase, update on, 560 (July)
anastrozole tablets
  Arimidex, update on, 871 (Nov)
anemia in end-stage renal disease
  comparative considerations of parenteral iron products for, 498 (June)
angina
  fatty acid oxidation agent with minimum hemodynamic effects, effective for, 446 (May)
antihemophilic factor, recombinant
  Helixate FS, update on, 632 (Aug)
  Kogenate FS, update on, 632 (Aug)
  ReFacto, update on, 393 (May)
antileukotriene agents
  role of agents in management of asthma, 38 (Jan)
antimicrobial cost and coverage
  software aids in determination of, 842 (Oct)
antimicrobial prophylaxis
  using CQI process to change surgical practices, 53 (Jan)
antimicrobial shortages
  forcing widespread use of nonpreferred therapies, survey finds, 307 (April)
apomorphine
  Uprima, Focus on, 573 (July)
appropriate use protocols
  palatable alternative to prior authorization, 77 (Jan)
argatroban injection
  Argatroban, update on, 709, (Sept)
arsenic trioxide injection
  Trisenox, update on, 868 (Nov)
aspirin/extended-release dipyridamole
  Aggrenox, update on, 16 (Jan)
asthma
  monocloncal antibiody improves symptoms, reduces steroid use in hard-to-treat disease, 214 (Mar)
  role of antileukotriene agents in management of, 38 (Jan)
atorvastatin calcium tablets
  Lipitor, update on, 209 (Mar)
atovaquone and proguanil HCl tablets
  Malarone, update on, 713 (Sept)
atrial fibrillation
  AHQR evidence report assesses therapies for new-onset disease, 721 (Sept)
attention-deficit/hyperactivity disorder
  intensive medication management superior to routine care in treatment of, 214 (Mar)
azelastine HCl ophthalmic solution 0.05%
  Optivar, update on, 560 (July)
azithromycin
  favored over recommended regimen for hospitalized patients with community-acquired pneumonia, 311 (April)

B

balsalazide disodium capsules
  Colazal, update on, 709 (Sept)
BCG intravesical immunotherapy with live, attenuated mycobacteria
  Pacis, update on, 394 (May)
beclomethasone dipropionate HFA inhalation aerosol
  Qvar, update on, 872 (Nov)
benefit design
  pitfalls to three-tier benefit design, advantages, glimpes of future design, 75 (Jan)
  three-tier offers superficial solution to utilization challenges, PacifiCare director says, 599 (July)
bexarotene capsules
  Targretin, update on, 206 (Mar)
bexarotene gel 1%
  Targretin Gel, 634 (Aug)
biotechnology drugs
  a critical assessment of agents (part 2), 256 (Mar)
bipolar disorder
  consensus report updates guidelines for Tx of, 479 (June)
breast cancer
  study supports first-line combination endocrine therapy for premenopausal women, 128 (Feb)
  tamoxifen for prevention called one of the most cost-effective interventions, 307 (April)
budesonide inhlation suspension, 0.25 mg and 0.5 mg
  Pulmicort Respules, update on, 796 (Oct)

C

caffeine citrate oral solution
  Cafcit Oral Solution, update on, 478 (June)
cancer
  ASCO meeting spotlights advances in, 644 (Aug)
candesartan cilexetil/hydrochlorothiazide tablets
  Atacand HCT, update on, 871 (Nov)
cefdinir capsules
  Omnicef, update on, 21 (Jan)
celecoxib
  prior authorization policy expected to save Medicaid HMO over $700,000 annually, 775 (Sept)
cerivastatin sodium tablets
  Baycol, update on, 713 (Sept)
cetrorelix acetate for injection
  Cetrotide, update on, 791 (Oct)
cevimeline HCl capsules
  Evoxac, update on, 205 (Mar)
chemotherapy
  protocol improves safe use of agents, 185 (Feb)
  rounding-down dose preserves vials, yields substantial cost savings, 369 (April)
choriogonadotropin alfa for injection
  Ovidrel, update on, 872 (Nov)
ciclopirox 0.77% gel
  Loprox Gel, update on, 390 (May)
ciclopirox topical solution 8%
  Penlac Nail Lacquer, update on, 390 (May)
ciprofloxacin
  associated with smaller antibiotic cost increases; resistance tied to ofloxacin (abstr), 87 (Jan)
  more efficacious, less costly then TMP/SMX for acute uncomplicated pyelonephritis (abstr), 454 (May)
cisapride tablets, suspension
  Propulsid, update on, 306 (April)
citalopram HBr oral solution
  Celexa, update on, 118 (Feb)
clarithromycin extended-release tablets
  Biaxin XL Filmtab, update on, 390 (May), 946 (Dec)
clonidine HCl injection
  Duraclon, update on, 306 (April)
  halves risk of myocardial ischemia throughout perioperative period, 874 (Nov)
colesevelam HCl tablets
  Welchol, update on, 557 (July)
congestive heart failure
  NSAIDs raise risk of hospitalization for, 479 (June)
constipation
  new approach targets 5-HT4 receptor, increases bowel frequency, 641 (Aug)
COX-2 agents
  automated pharmacy edits ensure proper use without excessive prior authorizations, 599 (July)
  celecoxib 'PA' policy expected to save Medicaid HMO over $700,000 annually, 775 (Sept)
  have differential renal effects in older hypertensive patients, 957 (Dec)
  impact on NSAID and GI drug use and cost in practice, 71 (Jan)
  long-term trial finds fewer serious GI effects compared with traditional NSAIDs, 480 (June)
  meloxicam (Mobic), Focus on, 317 (April)
  rofecoxib induces significantly fewer GI events than nonselective NSAIDs (abstr), 190 (Feb)
crotalide polyvalent immune Fab (ovine)
  CroFab, update on, 946 (Dec)

D

database analysis
  use of multiple logistic regression in, 832 (Oct)
decision analysis
  use in modeling the cost-effectiveness of oral vs SC sumatriptan, 532 (June)
deep vein thrombosis
  tinzaparin (Innohep), Focus on, 725 (Sept)
  tinzaparin (Innohep), update on, 710 (Sept)
depression
  nortriptyline superior to fluoxetine in first comparative trial for post-stroke side effect (abstr), 453 (May)
dexmedetomidine HCl injection
  Precedex, update on, 113 (Feb)
diabetes
  ACE inhbitor use slows ESRD progression at relatively low cost (abstr), 87 (Jan)
  antihypertension Tx with beta blockers, but not diuretics, raise risk of (abstr), 453 (May)
  nateglinide (Starlix), Focus on, 798

Subject Index

to volume 35

(Oct)
type 2 in the elderly, overview of treatment options, 580 (July)
diclofenac sodium gel 3%
Solaraze, update on, 945 (Dec)
didanosine tablets, buffered powder for oral solution
Videx, update on, 21 (Jan)
diltiazem HCl capsules
Cardizem CD, update on, 306 (April)
docetaxel for injection concentrate
Taxotere, update on, 117 (Feb)
doxercalciferol
Hectorol Injection, update on, 558 (July)
drug adherence
interventions to improve, a review of trials, 234 (Mar)
drug benchmarking
case study underscores value of, for physician groups, 605 (July)
drug benefit decision making
role of pharmacoeconomics in, results of a survey, 412 (May)
value judgments outweigh costs in, survey shows, 395 (May)
drug management
could common techniques be considered fraudulent activities, 690 (Aug)
model helps guide cost-effective drug use under outcomes-based reimbursement, 877 (Nov)
drug prices
legislators in 21 states launch efforts to emulate Maine's bold law, 641 (Aug)
policymakers, insurers decry; study factors driving spending growth, 542 (June)
prescribers care about, but lack info, 957 (Dec)
record drug cost trends, only slight easing ahead, report two major PBMs, 719 (Sept)
drug sampling program
PBM's generic program results in cost saves, promotes quality goals, 874 (Nov)
saves HMO nearly $200,000 in 9 months, 82 (Jan)
drug shortage
multihospital system assigns procurement specialist to spearhead issue, 694 (Aug)
drug spending
study findings increased volume, not rising prices, responsible for escalation in, 400 (May)
drug utilization controls
gains in use of fail to offset bigger gains in HMO drug spending, 120 (Feb)
drug value
broad new coalition aims to complement P &T Committees in assessing, 567 (July)
drug watch
allergic rhinitis and sinusitis, update on, 94 (Jan)
analgesic products, update on, 374 (April)
angina, dyslipidemic products, update on, 286 (Mar)
antibacterial agents, update on, 928 (Nov)
antiarrhythmics, agents for MI, ACS, update on, 1000 (Dec)
diabetic agents, update on, 618 (July)
gastrointestinal disorders, update on 544 (June)
hepatitis A, B, C, update on, 700 (Aug)
neurodegenerative diseases, 782 (Sept), 858 (Oct)
osteoporosis, agents for, update on, 196 (Feb)
psychotherapeutic agents, update on, 458 (May)
DTC advertising
health plans and payers attack, seek objective information on medication value, 616 (July)

E

eczema
tacrolimus ointment promises efficacy against, better tolerability than steroids, 403 (May)
eflornithine HCl cream, 13.9%
Vaniqa, update on, 716 (Sept)
electronic prescribing
reduces Rx costs, boosts generic use, 24 (Jan)
eletriptan
clinical claims questioned, (letter), 612 (July)
Relpax, Focus on, 129 (Feb)
epilepsy
oxcarbazepine (Trileptal), Focus on, 219 (Mar)
epoetin alfa for injection
Epogen, update on, 10 (Jan)
eptifibatide
reduces complications of stenting procedure, is less costly than standard agent, 445 (May)
erectile dysfunction
apomorphine (Uprima), Focus on, 573 (July)
esomeprazole
Nexium, Focus on, 882 (Nov)
estradiol/norethindrone acetate tablets
Activella, update on, 474 (June)
estradiol transdermal system
Vivelle, update on, 792 (Oct)
etanercept
Enbrel, update on, 631 (Aug), 946 (Dec)

F

federal legislation
AHCPR gets new name, focuses further on quality and safety of drug therapy, 284 (Mar)
Congress considers federal formulary rights bill, 27 (Jan)
Congress weighs action on Medicare drug benefit, Internet pharmacies, 456 (May)
FDA launches debate on renewing user fees and updating FDA Modernization Act, 925 (Nov)
formularies, cost issues examined at HHS drug pricing conference, 778 (Sept)
health care community under pressure to reduce medication errors, 191 (Feb)
new medical record privacy rules raise concerns for pharmacists, health plans, 372 (April)
pharmaceutical research, drug coverage in spotligt for year 2000, 92 (Jan)
policymakers move to expand Medicare drug benefit, Rx-to-OTC switch process, 698 (Aug)
public concerns for patient safety prompt changes in clinical trial policies, 853 (Oct)
tight election provides no mandate on health reform, pharmacy benefit, 992 (Dec)
fenofibrate capsules, micronized
Tricor, update on, 558 (July)
fexofenadine HCl capsules and tablets
Allegra, update on, 387 (May)
fluoxetine HCl capsules
Sarafem, update on, 632 (Aug)
fluticasone propionate
Flovent Diskus, update on, 946 (Dec)
fluticasone proprionate and salmeterol inhalation powder
Advair Diskus, update on, 871 (Nov)
fluvastatin
Lescol XL, update on, 946 (Dec)
follitropin alfa for injection
Gonal-F, update on, 714 (Sept)
formularies
experts examine formularies plus cost issues at HHS drug pricing conference, 778 (Sept)
formulary submission guidelines
AMCP unveils its Format for, begins dissemination efforts, 950 (Dec)
data requirements for manufacturers, Regence BlueShield's experience, 514 (June)

G

gabapentin oral solution
Neurontin, update on 393 (May)
gadoversetamide injection
OptiMARK, update on, 301 (April)
gatifloxacin tablets, injection
Tequin, update on, 114 (Feb)
gemifloxacin
Factive, Focus on, 961 (Dec)
gemtuzumab ozogamicin for injection
Mylotarg, update on, 553 (July)
glyburide and metformin HCl tablets
Glucovance, update on, 710 (Sept)
GP IIb/IIIa inhibitor therapy
cost effective, but not cost saving in acute coronary syndrome, 363 (April)
less costly agent reduces complications of stenting procedure, 445 (May)
use with fibrinolytics for acute MI, 738 (Sept)
gram-positive infections
Linezolid (Zyvox), Focus on, 483 (June)

H

HDL cholesterol
statin/niacin combo produces dramtic increase in, 445 (May)
heart failure
ELITE II, BEST fall short of earlier studies' promise in, 78 (Jan)
LMWH reduces thromboembolic events in patients with, 78 (Jan)
pathway increases ACE inhibitor prescribing, 185 (Feb)
heparin (low molecular weight)
home LMWH bridge therapy post cardiac valve sugery is safe, effective, cost saving, 990 (Dec)
review of their role for unstable angina/non-Q-wave MI, 970 (Dec)
tinzaparin (Innohep), Focus on, 725 (Sept)
hepatitis B vaccine (recombinant)
Recombivax HB, update on, 394 (May)
hepatitis C
cost-effectiveness analysis of interferon α-2b with ribavirin, 681 (Aug)
pegylated interferon promises effective treatment for, 125 (Feb)
hetastarch-for-albumin switch savings seen with, 696 (Aug)
HIV treatment
bacterial resistance to TMP-SMX up markedly, particularly among infected patients (abstr), 190 (Feb)
study boosts role of NNRTI-based triple therapy as initial Rx for, 120 (Feb)
hypercholesterolemia
evaluation of CYP3A4 drug interactions with HMG-CoA reductase inhibitors in, 343 (April)
quality assurance program meets NCEP goals, lowers statin costs, 448 (May)
hypertension
interim ALLHAT results lead to recommendations against alpha blockers in, 395 (May)

Subject Index

to volume 35

review of trials of interventions to improve adherence of drugs to treat, 234 (Mar)
treatment with beta blockers, but not diuretics, raises diabetes risk (abstr), 453 (May)
hypnotics
assessing the nonbenzodiazepines for insomnia management, 894 (Nov)

I

inamrinone
Amrinone, update on, 394 (May)
indigent care clinic
medications and disease states encountered at one, 361 (April)
procurement program leads to large return on investment, justifies salary outlay, 918 (Nov)
infliximab for IV injection
Remicade, update on, 10 (Jan)
influenza
cost effectiveness of zanamivir and oseltamivir, 979 (Dec)
current and potential therapeutic roles of the new neuraminidase inhibitors, 812 (Oct)
pharmaceconomic model to evaluate influenza treatments, 169 (Feb)
insomnia
assessing the nonbenzodiazepines for insomnia management, 894 (Nov)
insulin aspart (rDNA origin) injection
NovoLog, update on, 634 (Aug)
insulin glargine injection
Lantus, update on, 478 (June)
insulin lispro injection (rDNA origin)
Humalog, update on, 478 (June)
Humalog Mix 50/50, update on 305 (April)
insulin lispro protamine suspension
Humalog Mix 75/25, update on, 305 (April)
interferon α-2b with ribavirin
cost-effectiveness analysis for chronic hepatitis C, 681 (Aug)
interferon, beta 1a
early treatment slow onset of clinically definite MS, 952 (Dec)
interferon, beta 1b
cost utility analysis finds drug unjustified for secondary progressive MS, 126 (Feb)
interferon, gamma-1b injection
Actimmune, update on, 302 (April)
interferon, pegylated
promises effective treatment for hepatitis C and related cirrhosis, 125 (Feb)
irinotecan HCl injection
Camptosar, update on, 477 (June)
iron products for anemia
for end-stage renal disease, comparative considerations, 498 (June)
irritable bowel syndrome
Alosetron (Lotronex), Focus on, 404 (May)

L

leuprolide acetate implant
Viadur, update on, 394 (May)
levetiracetam tablets
Keppra, update on, 9 (Jan)
levobetaxolol HCL ophthalmic
Betaxon, update on, 297 (April)
levocarnitine injection
Carnitor, update on, 117 (Feb)
levofloxacin ophthalmic solution 0.5%
Quixin, update on, 796 (Oct)
levofloxacin tablets, injection
Levaquin, update on, 305 (April), 872 (Nov)
linezolid injection, tablets, oral suspension
Focus on, 483 (June)
Zyvox, update on, 474 (June)
lopinavir/ritonavir
Kaletra, update on, 867 (Nov)
low molecular weight heparin
home LMWH bridge therapy post cardiac valve sugery is safe, effective, cost saving, 990 (Dec)
reduces thromboembolic events in patients with acute heart failure, 78 (Jan)
review of their role for unstable angina/non-Q-wave MI, 970 (Dec)
tinzaparin (Innohep), Focus on, 725 (Sept)

M

melanoma
tamoxifen/cisplatin regimen shows promise as potential new standard for high-risk cases, 722 (Sept)
meloxicam
Mobic, Focus on, 317 (April)
update on, 472 (June)
mequinol 2%/tretinoin 0.01% topical solution
Solage, update on, 114 (Feb)
medroxyprogesterone acetate/estradiol cypionate injectable suspension
Lunelle, update on, 945 (Dec)
metformin
Glucophage XR, update on, 946 (Dec)
methylphenidate HCl tablets
extended-release tablets CII, Concerta, update on, 714 (Sept)
Metadate ER, update on 306 (April)
mifepristone tablets
Mifeprex, update on 868 (Nov)
migraine
eletriptan (Relpax), Focus on, 129 (Feb)
mitoxantrone for injection
Novantrone, update on, 936 (Dec)
mometasone furoate monohydrate
Nasonex, update on, 10 (Jan)
montelukast sodium chewable tablets
Singulair, update on, 388 (May)
moxifloxacin HCl tablets
Avelox, update on, 110 (Feb)
multiple sclerosis
cost-utility analysis finds IFN-beta-1b unjustified for secondary progressive form, 126 (Feb)
early treatment with interferon beta-1a slow onset of , 952 (Dec)
mycophenolate mofetil capsules, tablets, oral suspension, injection
CellCept, update on, 792 (Oct)
myocardial infarction
fibrinolysis plus GP IIb/IIIa receptor blockage for management of acute, 738 (Sept)
no need to wait to start lipid-lowering drugs following event, 447 (May)
sestamibi perfusion scans in ED rule out MI, reduce unnecessary hospitalization, 81 (Jan)
tenecteplase (TNKase), Focus on, 647 (Aug)
two studies question use of thrombolytics for, in patients over age 75, 568 (July)

N

nateglinide
Starlix, Focus on, 798 (Oct)
NCQA
revised pharmacy standard aims at collaborative care, not specific mandates, 604 (July)
nedocromil sodium ophthalmic solution 2%
Alocril, update on, 118 (Feb)
nelfinavir mesylate
Viracept, update on, 21 (Jan)
niacin
combined with statin, produces dramatic increase in HDL cholesterol, 445 (May)
nimodipine capsules
Nimotop, update on, 872 (Nov)
nitric oxide for inhalation
INOmax, update on, 110 (Feb)
nortriptyline
superior to fluoxetine in first comparative trial for post-stroke depression (abstr), 453 (May)
NSAIDs
impact of COX-2 agents on NSAID and GI drug use and costs, 71 (Jan)
meloxicam (Mobic), Focus on, 317 (April)
modeling software aids in cost assessment of, 368 (April)
raise risk of hospitalization for CHF, 479 (June)
review of factors guiding formulary selection, 142 (Feb)
rofecoxib induces significantly fewer GI events than nonselective agents (abstr), 190 (Feb)

O

olanzapine tablets
Zyprexa, update on, 388 (May), 946 (Dec)
Zyprexa Zydis, disintegrating tablets, update on, 560 (July)
outcomes assessments
selecting patient risk factors for risk adjustment in, 595 (July)
using epidemiologic principles to design outcomes assessments, 765 (Sept)
outcomes management
conducting an internal needs analysis to select tools for outcomes projects, 274 (Mar)
improvement of, in the elderly, 904 (Nov)
risk adjustment methods for health outcomes assessments, general approaches, 426 (May)
use of technology to improve drug therapy outcomes, 65 (Jan)
oxcarbazepine tablets
Trileptal, Focus on, 219 (Mar)
Trileptal, update on, 206 (Mar)

P

P & T Committee
broad new coalition aims to complement, in assessing drug value, 567 (July)
computer tool lets members assess Tx classes with own weightings, product ratings, 603 (July)
managed pharmacy veteran sees shortage in support staffing, questions future of drug benefit, 367 (April)
rationale and successes with a decentralized committee, 752 (Sept)
revamping structure and process to improve efficiency/productivity, 282 (Mar)
pantoprazole
Protonix, Focus on, 28, (Jan)
Protonix, update on, 205 (Mar)
Parkinson's disease
treatment of motor complications in advancing disease, 654 (Aug)
PBMs
record drug cost trends, only slight easing ahead, predict two major companies, 719 (Sept)
pemirolast potassium ophthalmic solution
Alamast, update on, 627 (Aug)
pharmaceutical care
clinicians document actual savings due to practice of, 610 (July)
pharmacist services
two studies show cost-savings value

Subject Index

to volume 35

of, 22 (Jan)
value applied to ambulatory renal transplant setting, study finds, 369 (April)
pharmacoeconomics
critical evaluation of a decision-analytic model of BPH treatment options, 353 (April)
pharmacoeconomic model to evaluate new influenza treatments, 169 (Feb)
where we are, where we need to go (commentary), 422 (May)
pneumococcal 7-valent conjugate vaccine (diptheria CRM 197 protein)
Prevnar, update on, 302 (April)
pneumonia, community-acquired
cost-effectiveness analysis favors azithromycin over recommended regimen, 311 (April)
macrolides, beta-lactams earmarked as workhorse drugs in new CDC recommendations, 642 (Aug)
poractant alfa intratracheal suspension
Curosurf, update on, 9 (Jan)
pravastatin sodium tablets
Pravachol, update on 209 (Mar)
preoperative antibiotic administration time
improvement seen with multidisciplinary team approach, 541 (June)
prescribing
PBM's plan to improve, in the elderly, provides foundation for others, 283 (Mar)
prior authorization
appropriate use protocols, as an alternative to, 77 (Jan)
prostate cancer
high-dose bicalutamide shows promise as castration-free Tx for nonmetastatic, 570 (July)
protease inhibitor
reduces AIDS therapy costs, opportunistic infections, 540 (June)
proton pump inhibitors
esomeprazole outperforms omeprazole in esophagitis healing, 570 (July)
pantoprazole (Protonix), Focus on, 28 (Jan)
pyelonephritis
ciprofloxacin more efficacious, less costly than TMP/SMX for acute uncomplicated (abstr), 454 (May)

Q

quinapril HCl/hydrochlorothiazide tablets
Accuretic, update on, 213 (Mar)

R

ramipril capsules
Altace, update on, 936 (Dec)
renal disease (end-stage)
parenteral iron products for, 498 (June)
renal dosing policy
hospital anticipates annual savings of up to $200,000, 696 (Aug)
renal failure (acute)
overview of current and potential therapies, 669 (Aug)
risedronate sodium tablets
Actonel, update on, 477 (June)
rivastigmine tartrate capsules, oral solution
Exelon, update on, 471 (June)
rosiglitazone maleate tablets
Avandia, update on, 388 (May)

S

17-beta-estradiol/norgestimate
Ortho-Prefest, update on, 16 (Jan)
scorecard
review of antiarthritic agents, fluoroquinolones, 467 (June)
review of anticonvulsants, PPIs, 917 (Nov)
review of LMWHs, platelet aggregation inhibitors, 770 (Sept)
review of SSRIs, thiazolidinediones, 296 (Mar)
sertraline HCl tablets
Zoloft, update on, 13 (Jan)
sertraline oral concentrate
Zoloft, update on, 118 (Feb)
sevelamer HCl tablets
Renagel, update on, 716 (Sept)
sildenafil
identifying and correcting inappropriate use in a state Medicaid population, 540 (June)
simvastatin tablets
Zocor, update on, 13 (Jan)
sinusitis
new guidelines endorse beta-lactams, cephalosporins for, 797 (Oct)
somatropin (rDNA origin) for injectable suspension
Genotropin, update on, 631 (Aug)
Nutropin Depot, update on, 118 (Feb)
sotalol HCl capsules
Betapace AF, update on, 305 (April)
statins
observational trials link statins with bone benefits, 719 (Sept)
stroke
review of advances in prevention and acute intervention, 328 (April)
sumatriptan
use of decision analysis in modeling cost-effectiveness of oral vs SC, 532 (June)
surgical antimicrobial prophylaxis practices
improving the CQI process (letter), 295 (Mar)
using CQI process to change, 53 (Jan)
switch programs
pharmacist-led IV-to-oral antibiotic switch program key to project sucess, 775 (Sept)
savings seen with hetastarch-for-albumin switch, 696 (Aug)
synthetic conjugated estrogens, A, tablets
Cenestin, update on, 394 (May)

T

tacrolimus
ointment promises efficacy against eczema with better tolerability than steroids, 403 (May)
tamoxifen
cost-effective intervention for breast cancer prevention, 307 (April)
Nolvadex, update on, 631 (Aug)
tazarotene
Tazorac Cream 0.05%, 0.1%, update on, 946 (Dec)
tenecteplase
TNKase, Focus on, 647 (Aug)
TNKase, update on, 553 (July)
testosterone gel
AndroGel 1%, update on, 390 (May)
therapeutic buy-up program
plus copay increase yields 16%, 6-month savings for health plan, 83 (Jan)
thiazolidinediones
side effects comparison elicits clarification (letter), 914 (Nov)
three-tier benefit
pitfalls to development, advantages, glimpses of future designs, 75 (Jan)
savings appear greater with, over closed formulary, health plan finds, 363 (April)
three-tier offers superficial solution to utilization challenges, PacifiCare director says, 599 (July)
thrombolytics
two studies question use of, for acute MI after age 75, 568 (July)
tiagabine HCl tablets
Gabitril, update on, 560 (July)
tinzaparin sodium injection
Innohep, Focus on, 725 (Sept)
Innohep, update on, 710 (Sept)
topiramate tablets, sprinkle capsules
Topamax, update on, 560 (July)
trastuzumab
Herceptin, update on, 560 (July)
trimethoprim HCl oral solution
Primsol solution, update on 209 (Mar)
triptorelin pamoate for injection
Telstar Depot, update on, 627 (Aug)
troglitazone tablets
Rezulin, update on, 306 (April)

U

Unoprostone isopropyl ophthalmic solution, 0.15%
Rescula, update on, 791 (Oct)

V

venlafaxine HCl extended-release capsules
Effexor XR, update on, 714 (Sept)
verteporfin for injection
Visudyne, update on, 472 (June)

Z

zanamivir for inhalation
Relenza, update on, 557 (July)
zonisamide capsules
Zonegran, update on, 383 (May)

Author Index

to Volume 35

A

Abarca, Jacob: See Armstrong, Edward P.
Abarca, Jacob; Armstrong, Edward P.: How to use multiple logistic regression in retrospective database analysis, 832 (Oct)
Ahlskog, J. Eric: Treatment of motor complications in advancing Parkinson's disease: Which drugs and when? 654 (Aug)
Alldredge, Brian K.: See Burkiewicz, Jill S.
Armstrong, Edward P.; Abarca Jacob: Pharmacoeconomic model to evaluate new influenza treatments, 169 (Feb)
Armstrong, Edward P.; Khan, Zeba M.; Perry, Andrew S.; Perri, Lisa R.: The cost effectiveness of zanamivir and oseltamivir for influenza treatment, 979 (Dec)
See Abarca, Jacob.
See Joish, Vivay N.
See Motheral, Brenda R.
Arroliga, Alejandro C.: See Horan, Jennifer L.

B

Bailie, George R.; Johnson, Curtis A.; Mason, Nancy A.: Parenteral iron products for anemia in end-stage renal disease: Comparative considerations, 498 (June)
Berger. Marc L.: See Morrison, Albert
Bobek, Mary Beth: See Horan, Jennifer L.
Boyce, Eric G.; Takiya, Liza: Nonsteroidal anti-inflammatory drugs: Review of factors guiding formulary selection, 142 (Feb)
Brockington, Carolyn D.; Lyden, Patrick D.: Stroke prevention and acute intervention: Review of recent advances, 328 (April)
Burkiewicz, Jill S.; Chan, Jeannie D.; Alldredge, Brian K.: Focus on eletriptan: Serotonin 5-HT 1B/1D receptor agonist for the acute treatment of migraine, 129 (Feb)

C

Chan, Jeannie D.: See Burkiewicz, Jill S.
Chow, Moses S. S.: See Chow, Sheryl L.
Chow, Sheryl L.; Tomlinson, Brian; Chow, Moses S.S.: Pharmacologic management of insomnia: Assessing the nonbenzodiazepine hypnotics, 894 (Nov)
Cox, Emily: See Motheral, Brenda R.
Cupo-Abbott, Jennifer; Louie, Stan G.; Rho, Jay P.: Focus on linezolid: A synthetic oxazolidinone antimicrobial for treatment of serious gram-positive infections, 483 (June)

D

da Silva, Barbara A.; Molitch, Mark E.: Pharmacologic management of type 2 diabetes in the elderly: Overview of treatment options, 580 (July)

E

Eavy, Gene R.; Swinkey, Nancy J.: Rehan, Ahmed: Decentralizing the P & T committee: Rationale and successes, 752 (Sept)

F

Fairman, Kathleen. See Motheral, Brenda R.
Feret, Bret: Focus on apomorphine: A sublingual dopamine agonist for the treatment of erectile dysfunction, 573 (July)
Fullerton, D.S. Pete; Sullivan, Sean: Regence BlueShield's mandatory data submission requirement for manufacturers: A progress report, 514 (June)

G

Goff, Debra A.; Sierawski, Sondra J.; Lubowski, Teresa J.: Software-aided evaluation of antibiotic cost and coverage: Example of empiric therapy for intraperitoneal abscess infections, 842 (Oct)
Gonzalez, Luis S.: New neuraminidase inhibitors for influenza: Current and potential therapeutic roles, 812 (Oct)
Grizzle, Amy J.: Critical evaluation of a decision-analysis model of BPH treatment options, 353 (April)
See Motheral, Brenda R.
Gross, Paige R.: See Skledar, Susan J.

H

Hall, Tonya; Kendrach, Michael; Nowack, Kimberly: Medications and disease states encountered at one indigent care clinic, 361 (April)
Heimboldt, Kristin: See Lott, Rex S.
Hilleman, Daniel E.: New approaches to the management of AMI: Fibrinolysis plus GP IIb/IIIa receptor blockade, 738 (Sept)
Horan, Jennifer L.; Bobek, Mary Beth; Arroliga, Alejandro C.: Acute renal failure: Overview of current and potential therapies, 669 (Aug)

J

Johnson, Curtis A.: See Bailie, George R.
Johnson, Margaret M.: Defining the role of antileukotriene agents in the management of asthma, 38 (Jan)
Johnson, Nelda: Conducting an internal needs analysis to select tools for outcomes projects, 274 (Mar)
Improving outcomes in the elderly, 904 (Nov)
Using epidemiologic principles to design outcomes assessments, 765 (Sept)
The use of technology to improve drug therapy outcomes, 65 (Jan)
Johnson, Nelda; Shin, Grace: Risk adjustment methods for health outcomes assessments: General approaches, 426 (May)
Selecting patient factors for risk adjustment in health outcomes assessments, 595 (July)
Joish, Vijay N.; Armstrong, Edward P.: Use of decision analysis in modeling the cost-effectiveness of oral vs SC sumatriptan, 532 (June)

K

Kendrach, Michael: See Hall, Tonya
Khan, Zeba M.: See Armstrong, Edward P.

L

Lomaestro, Ben M.: Focus on gemifloxicin: A broad-spectrum oral quinolone for treatment of respiratory and urinary tract infections, 961 (Dec)
Lott, Rex S.; Heimboldt Kristin: Focus on oxcarbazepine: A carbamazepine analogue for partial seizures in adults and children with epilepsy, 219 (Mar)
Louie, Stan G.: See Cupo-Abbott, Jennifer
Lubowski, Teresa J.: See Goff, Debra A.
Lyden, Patrick D.: See Brockington, Carolyn D.
Lyles, Alan: Pharmacoeconomics in 2000: Where we are, where we need to go, 422 (May)

M

Malone, Daniel C.: Cost-effectiveness analysis of interferon α-2b with ribavirin for chronic hepatitis C infection, 681 (Aug)
Mason, Nancy A.: See Bailie, George R.
Matalka, Mazen S.: See Reinhard, Felicia
Molitch Mark E.: See Da Silva, Barbara A.
Morrison, Alan; Wertheimer, Albert I.; Berger, Marc L.: Interventions to improve antihypertensive drug adherence, 234 (Mar)
Motheral, Brenda R.; Grizzle, Amy J.; Armstrong, Edward P.; Cox, Emily, Fairman, Kathleen: Role of pharmacoeconomics in drug benefit decision-making: Results of a survey, 412 (May)

N

Nowack, Kimberly: See Hall, Tonya.

O

Oatis, Ghitiana M.; Stowers, Allan D.: Conversion from amlodipine to felodipine ER: Did the change fulfill expectations, 435 (May)

P

Perri, Lisa R.: See Armstrong, Edward P.
Perry, Andrew S.: See Armstrong, Edward P.
Pillay, Sharmani: See Reddy, Prabashni

R

Ravnan, Marcus C.: See Reinhard, Felicia
Reddy, Prabashni: Focus on alosetron: A 5-HT3 receptor antagonist for treatment of irritable bowel syndrome, 404 (May)
Reddy, Prabashni; Pillay, Sharmani: Focus on tinzaparin: A once-daily low-molecular weight heparin for the treatment of deep vein thrombosis, 725 (Sept)
Rehan, Ahmed: See Eavy, Gene R.
Reinhard, Felicia; Ravnan, Marcus C.; Matalka, Mazen S.: Low-molecular-weight heparins: Review of their role for unstable angina/non-Q-wave MI, 970 (Dec)
Rho, Jay P.: See Cupo-Abbott, Jennifer

S

Schrand, Linda M.: Recent additions to the growing armamentarium: A critical assessment, 256 (Mar)
Schrand, Linda M.; Spanheimer, Robert G.: Focus on nateglinide: A new member of the meglitinide family for postprandial glucose control in type 2 diabetes, 798 (Oct)
Shin, Grace: See Johnson, Nelda.
Siepler, John K.: Focus on meloxicam: A COX-2-specific NSAID for the treatment of osteoarthritis, 317 (April)
Sierawski, Sondra J.: See Goff, Debra A.
Skledar, Susan J.; Gross, Paige R.: Using a CQI process to change surgical antimicrobial prophylaxis practices, 53 (Jan)

Author Index

to volume 35

Smith, Candace: Focus on pantoprazole: A new benzimidazole proton pump inhibitor for oral and IV administration, 28 (Jan)
Spanheimer, Robert D.: See Schrand, Linda M.
Stowers, Allan D.: See Oatis, Ghitiana M.
Sullivan, Sean: See Fullerton, D.S. Pete.
Swinkey, Nancy J.: See Eavy, Gene R.

T

Takiya, Liza: See Boyce, Eric G.
Tomlinson, Brian: See Chow, Sheryl L.
Tsikouris, James P.; White, C. Michael: Focus on tenecteplase: A novel fibrin-specific thrombolytic agent for treatment of acute myocardial infarction, 547 (Aug)

W

Wechsler, Jill: AHCPR gets new name, focuses further on quality and safety of drug therapy, 284 (Mar)
Congress weighs action on Medicare drug benefit, Internet pharmacies, 456 (May)
Experts examine formularies, cost issues at HHS drug pricing conference, 778 (Sept)
FDA launches debate on renewing user fees and updating FDA Modernization Act, 925 (Nov)
Health care community under pressure to reduce medication errors, 191 (Feb)
Health plans and payers attack DTC advertising, seek objective information on medication value, 616 (July)
New medical record privacy rules raise concerns for pharmacists, health plans, 372 (April)
Pharmaceutical research, drug coverage in spotlight for year 2000, 92 (Jan)
Policymakers, insurers decry drug prices, study factors driving spending growth, 542 (June)
Policymakers move to expand Medicare drug benefit, Rx-to-OTC switch process, 698 (Aug)
Public concerns for patient safety prompt changes in clinical trial policies, 853 (Oct)
Tight election provides no mandate on health reform, pharmacy benefits, 992 (Dec)
Wertheimer, Albert I.: See Morrison, Albert
White, C. Michael: An evaluation of CYP 3A4 drug interactions with HMG-CoA reductase inhibitors, 343 (April)
See Tsikouris, James P.

Z

Zimmermann, Anthony E.: Focus on esomeprazole: A novel proton pump inhibitor for the treatment of acid-related disorders, 882 (Nov)

Appreciation to Our Reviewers

Sixty-two health care professionals served as external reviewers for manuscripts submitted to Formulary from November 1999 through October 2000. The *Formulary* staff editors express appreciation to these reviewers who have helped to maintain quality and consistency in the published articles.

Wm. Michael Alberts, MD,
Paul J. Barrett, PharmD, BCPS
Cristina Bello, PharmD
Frederick H. Bender, PharmD
Crystal S. Blankenship, PharmD
Brenda V. Borders-Hemphill, PharmD
Morgan S. Bron, PharmD
David S. Burgess, PharmD
Eugene Y. Cheng, MD
Pang Chong, PharmD
Novena T. Chui, PharmD
Irene Contreras, PharmD
Vicki Crane, MBA, RPh
Eric J. Culley, PharmD
Ralph E. Cutler, MD
John H. Eddy, RPh
Steven Erickson, PharmD
Jacqueline L. Fein, MS, PharmD
Beverly Franklin-Thompson, PharmD
Joseph Gruber, RPh
LaDonna S. Hale, PharmD
Albert W. Helmeczi, MS, RPh
Frederick M. Jacobsen, MD, MPH
Robert A. Julien, MD, PhD
Alan Todd Kaell, MD
Howard M. Karp, DO
Heather Roni Kass, PharmD
Michael Kendrach, PharmD
Mandy C. Leonard, BS, PharmD
Mitchell Marsh, PharmD
Dean Matanin, PharmD
Veronica Moriarty, PharmD
Paul Oesterman, PharmD
David Parra, PharmD
David C. Perlman, MD
Bruce G. Pollock, MD, PhD
Curt W. Quap, MSc, RPh
Robert Quercia, MS
Jay P. Rho, PharmD
Mark Wm. Rolfe, MD
Gary E. Sander, MD, PhD
Cynthia A. Sanoski, PharmD
Maureen E. Savitsky, PharmD
Linda Schrand, PharmD
Brian M. Schwartz, MD
Stephen D. Sears, MD
Sonia Shaw, PharmD
Domenic A. Sica, MD
Angela W. Smith, PharmD
Allan J. Stahl, MD
Gary E. Stein, PharmD
Gregory M. Susla, PharmD
Marc A. Sweeney, PharmD
James E. Szalados, MD, MBA, MHA
F. Randy Vogenberg, RPh, PhD
Terrence R. Walker, PharmD
Elizabeth Welter, RPh
James W. Wheless, MD
Dewey T. Wong, PharmD
Betsy S. Woodall, PharmD
James M. Wooten, PharmD
Fred A. Zar, MD